13 Sep 2016 07:00
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company" or the "Group")
Appointment of Chairman
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.
Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will benefit Venn.
Tony Richardson, Chief Executive Officer of Venn said: "I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan's experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders."
Mr. Wood has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM Rules and the ESM Rules.
Current directorships or partnerships | Directorships or partnerships in the last five years |
Oxehealth Limited | Trustmarque Solutions Limited |
Ardvarna Investment Capital Limited | Healthcare Homes Holdings Limited |
Eclipse Film Partnership No. 22 LLP | HWH Plus Limited |
The Augusta Film Limited Liability Partnership | HWH Group Limited |
WCI Group Trustee Company Limited | |
Creare Franchise Limited | |
Creare Communications (UK) Limited | |
Creare Communications (Holdings) Limited | |
Care UK (Urgent Care) Holdings Limited |
Mr. Wood does not hold any ordinary shares in Venn Life Sciences.
Venn Life Sciences Holdings Plc | www.vennlifesciences.com | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | ||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | |
Paul Burke (Corporate Broking) | ||
Hybridan LLP (Co-Broker) | ||
Claire Louise Noyce | Tel: +44(0)20 3764 2341 | |
Walbrook PR Ltd | Tel: +44(0)20 7933 8787 or venn@walbrookpr.com | |
Paul McManus | Mob: +44(0) 7980 541 893 | |
About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.